Skip to main content

You are here

Our work with the pharmaceutical industry

The pharmaceutical industry has a crucial role to play in improving diagnosis and treatment options for those living with lung disease.

As a charity we engage with the pharmaceutical sector in some areas to drive progress and improvements within respiratory disease around prevention, diagnosis, and treatments to promote better outcomes for patients. 

When working with industry, we will ensure that any such relationships do not affect our ability to offer independent and unbiased patient information, or influence our campaigning, research or fundraising activities. We will follow the below principles:  

  • Any partnership entered into will not compromise our independent status and must align with our mission and strategic aims. We will ensure that our editorial independence is maintained so that we are free to comment both positively and negatively about pharmaceutical companies and their products. 
  • We will ensure that we work with a variety of pharmaceutical companies, giving no preference to any one company in particular. Where activities being supported by industry are linked to influencing or campaigning activities, we will seek to work with a minimum of two partners in order to maintain our independence and impartiality.  
  • Because it’s important that we are independent when campaigning for better access to a drug or treatment, we will not accept funding from a pharmaceutical company to support campaigning activity or lobbying for access to specific drugs or treatment that is owned by them.  
  • To ensure our independent status, we will limit the total amount that we receive from the pharmaceutical sector to 15% of our total income in any given financial year (excludes any funding received for the Taskforce for Lung Health). We will limit the amount that any individual pharmaceutical company can donate to 5% of our total income in any given financial year. 
  • Partnerships must comply with relevant codes including the ABPI Code of Practice for the pharmaceutical industry (or appropriate equivalent), Medicines and Healthcare products Regulatory Agency (MHRA), the Fundraising Regulator and the Institute of Fundraising’s Codes of Practice. 
  • We will not align our brands with the promotion of a specific branded drug. We will not directly endorse any third party, its products or services. 
  • We will work with members of the pharmaceutical industry to share knowledge and expertise, such as through the Taskforce for Lung Health. This may involve the participation of the pharmaceutical industry in organised events such as: private or public meetings; training events; advisory board meetings; and market research events. 
  • We will not partner with companies involved in the manufacture, sale or direct promotion of tobacco or heated tobacco products (this does not include places that sell tobacco products such as supermarkets). This includes pharmaceutical companies owned wholly or in part by the tobacco industry. Where organisations have a third-party association with the tobacco industry any potential partnership will be reviewed on a case-by-case basis. 

We thank the following companies for their support throughout 2019 and 2020

  • Chiesi 
  • Janssen 
  • J&J 
  • MSD 
  • AstraZeneca 
  • GSK 
  • Novartis 
  • Pfizer 
  • Seqirus 
  • Sanofi 
  • Takeda 
  • Verona Pharma 
  • Amgen 
  • Medtronic